Article

Angina by the Numbers - Mortality, Incidence, Prevalence, and other Angina Statistics

Below are select statistics on the prevalence, incidence, and mortality rates associated with angina pectoris in the US.

Below are select statistics on the prevalence, incidence, and mortality rates associated with angina pectoris in the US.

445,687 deaths in the United States in 2005 (about one of every five deaths) were due to coronary heart disease (CHD).

According to the National Heart, Lung, and Blood Institute's Atherosclerotic Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS), there are 1,260,000 new and recurrent coronary attacks per year — about 37% of people who experience a coronary attack in a given year die from it.

Nearly 17,000,000 victims of angina, heart attack, and other forms of CHD are still living (8.7 million males and 8.1 million females).

From 1995 to 2005, the death rate from CHD declined 34%, but total deaths declined only 19%.

An estimated 10 million people in the US suffer from angina.

According to the Framingham Heart Study, an estimated 500,000 new cases of stable angina occur each year.

The estimated age-adjusted prevalence of angina in women age 20 and older is 4.1% for non-Hispanic white women, 6.7% for non-Hispanic black women, and 4.5% for Mexican-American women. Rates for men in these three groups were 4.1%, 4.4% and, 3.5%, respectively.

The estimated age-adjusted prevalence of coronary heart disease in the US for non-Hispanic whites is 8.8% for men and 9% for women; for non-Hispanic blacks 9.6% for men and 7.8% for women; and for Mexican-Americans, 5.4% for men and 6.3% for women.

Source: American Heart Association

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.